Contents

Search

BRAF V600 mutation (THxID BRAF)

Indications: - elibigiblity for treatment of metastatic melanoma with vemurafenib (Zelboraf), dabrafenib (Tafinlar) or trametinib (Mekinist) Procedure: - polymerase chain reaction to identifpoint mutation at Val-600 in the BRAF gene Clinical significance: - mutation present in about 1/2 of late-stage melanomas

Related

cutaneous melanoma serine/threonine protein kinase B-raf; proto-oncogene B-Raf; p94; v-Raf murine sarcoma viral oncogene homolog B1 (BRAF BRAF1 RAFB1)

Specific

BRAF V600E mutation BRAF V600K mutation

General

gene mutation testing; gene mutation analysis

References

  1. FDA NEWS RELEASE: Aug. 17, 2011 FDA approves Zelboraf and companion diagnostic test for late-stage skin cancer
  2. FDA News Release: May 29, 2013 FDA approves two drugs, companion diagnostic test for advanced skin cancer. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm354199